Close Menu

Pfizer

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

The Wall Street Journal reports vaccine makers promise to not seek regulatory approval until there is evidence their SARS-CoV-2 vaccines are safe and effective.

Enhancement Avoidance

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

Trialing It Out

The New York Times reports Pfizer and BioNTech have also started a trial of their mRNA-based vaccine for SARS-CoV-2 in the US.

Centogene's data repository includes rare disease patient data including clinical information, health records, and a range of -omics data.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

The partners will glean real-world evidence from Syapse's network of health system partners with the aim of informing precision oncology approaches and advancing research.

Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.

Researchers are collecting genomic and clinical data on cancer patients outside of clinical trials to understand tumor biology, treatment efficacy, and care gaps.

The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.

Pages

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.